NOVARTIS-EGF100151



A Phase III, Randomized, Open-label, Multicenter Study Comparing GW572016 and Capecitabine (XELODA) versus Capecitabine in Women with Refractory Advanced or Metastatic Breast Cancer
lapatinib
EGF100151
NCT00078572
Cancer, Breast
Phase 3
 
September 2013